CAS: 39025-23-5; (Z)-Guggulsterone

该化合物是自然产生的一种来自Commiphora mukul树树树脂(通常称为guggul)的抗血清化合物,该化合物被归类为一种植物激素,以其潜在的治疗特性而闻名,特别是在传统医学中.Z-Gugulsterone展示了一系列生物活动,包括抗炎,抗氧化剂和脂质调控效应,在药理学和营养领域引起了兴趣.该产品经常被研究其在体重管理和胆固醇管制方面的潜在作用.该化合物的特征是其特定的立体化学特征,有助于其生物活动.Zgugulsonone通常以固体或晶体物质的形式出现,在有机溶剂中溶解,但水溶解性有限.其安全和功效是正在进行的研究的主题,在作为补充食品时,使用者在使用前应当咨询保健专业人员,特别是与其他药物或健康条件相结合.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

C&L通报REACH预注册

上下游产品

CAS号3347-58-8 5,17(20)-E-preg...

合成工艺路线路线简述

    📜16,17-环氧孕烯醇酮置于环己酮,Aluminum Isopropoxide,对甲苯磺酸,一水合肼,Potassium Hydroxide体系中,用 甲苯,二乙二醇,苯 用作溶剂,化学反应 6.0H,反应生成孕二烯二酮
    参考文献:A Regioselective Synthesis Of E-Guggulsterone
    标题:A Regioselective Synthesis Of E-Guggulsterone
    摘要:我们通过肼还原和奥本华氧化两步成功地从 16,17-环氧孕烯醇酮制备了 E-古古甾酮,收率达到 84%.此外,通过热,光(Hn)和酸催化诱导异构化,将e-古古甾酮转化为相应的z异构体.
    Doi:10.3390/molecules16054165

    海关参考信息

    专利信息


    专利号:US-2005085452-A1
    优先权日:2002-09-03
    标 题:Process for the synthesis of pharmacologically active (z/e)-guggulsterones
    发明人：GOKARAJU GANGA R; GOKARAJU RAMA R; GOTTUMUKKALA VENKATA S; SOMEPALLI VENKATESWARLU
    摘要:The invention relates to an improved process for producing pharmacologically active synthetic stereoisomeric mixture of guggulsterones (4) in the three steps. The mixture of gugguisterones consists of Z-guggulsterone [4,17(20)-trans-pregnadiene-3,16-dione] and E-guggulsterone [4,17(20)-cis-pregnadiene-3,16-dione] and could be in any relative ratio. This improved process comprises (a) epoxidation of 16-dehydropregnanolone acetate (1) with hydrogen peroxide (b) reduction of the so obtained epoxide (2) with hydrazine hydrate and (c) oxidation of the diol (3).

    专利号:WO-2004021975-A2
    优先权日:2002-09-03
    标题:An improved process for the synthesis of pharmacologically active (z/e)-guggulsterones

    专利号:WO-2004021975-A3
    优先权日:2002-09-03
    标 题 :An improved process for the synthesis of pharmacologically active (z/e)-guggulsterones

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Huang P, Zhao H, Dai H, Li J, Pan X, Pan W, Xia C, Liu F. FXR deficiency induced ferroptosis via modulation of the CBP-dependent p53 acetylation to suppress breast cancer growth and metastasis. Cell Death Dis. 2024 Nov 14;15(11):826. doi: 10.1038/s41419-024-07222-3.
    2: Liang X, Liu K, Jia X, Cheng C, Zhang M, Kong L, Li Q, Liu Z, Li M, Li J, Wang Y, Xu A. Suppressing FXR promotes antiviral effects of bile acids via enhancing the interferon transcription. Acta Pharm Sin B. 2024 Aug;14(8):3513-3527. doi: 10.1016/j.apsb.2024.05.005. Epub 2024 May 13.
    3: Li JP, Ye BL, Li Q, Zhang LL, Zhuang L, Yuan YW. FXR contributes to obstructive jaundice-induced vascular hyporeactivity in mesenteric arteries by reconstituting BKCa channels. Clin Res Hepatol Gastroenterol. 2024 Oct;48(8):102448. doi: 10.1016/j.clinre.2024.102448. Epub 2024 Aug 17. 15(2):148. doi: 10.1038/s41419-024-06495-y.

    合成参考文献


    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    参考文献:10.1186/1479-5876-6-14
    摘要:Deocaris CC, Widodo N, Wadhwa R, Kaul SC. Merger of Ayurveda and Tissue Culture-Based Functional Genomics: Inspirations from Systems Biology. Journal of Translational Medicine. 2008 Mar 18;6(1):14. doi: 10.1186/1479-5876-6-14.
    参考文献:10.1007/s11356-021-15594-8
    摘要:El Omari N, Bakha M, Imtara H, Guaouguaoua F, Balahbib A, Zengin G, Bouyahya A. Anticancer mechanisms of phytochemical compounds: focusing on epigenetic targets. Environmental Science and Pollution Research. 2021 Jul 26;28(35):47869–903. doi: 10.1007/s11356-021-15594-8.
    参考文献:10.1007/s11745-003-1173-y
    摘要:Cho KH, Park JY, Han JI, Jeong TS. Ligand-binding domain of farnesoid X receptor (FXR) had the highest sensitivity and activity among FXR variants in a fluorescence-based assay. Lipids. 2003 Nov;38(11):1149–56. doi: 10.1007/s11745-003-1173-y.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知